Lineage Cell Therapeutics enters collaboration with WDI for hearing loss program; up to $12M funding

Lineage Cell Therapeutics, Inc.

Multi-year research collaboration with William Demant Invest 2 Aps to advance ReSonance (ANPI) preclinical program for hearing loss.
WDI will fund up to $12 million in research costs over the approximate three-year term.
Objective: complete preclinical phase to achieve readiness for potential human clinical trials.
IP: jointly owned project results; each party retains background IP and platform technology.
If a party abandons, the continuing party may purchase the abandoning party's IP interest in the project.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.